Ballicules.com

Amantadine ER

GOCOVRI

What it isExtended-release NMDA antagonist with incompletely defined dopaminergic effects for levodopa dyskinesia and off episodes (GOCOVRI, 2017).

Why this oneIts bedtime dosing yields high morning levels, and it is the only drug labeled for levodopa-induced dyskinesia in Parkinson disease.

What limits itRenal accumulation causes confusion and hallucinations; livedo reticularis, edema, and orthostasis also limit use.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Parkinson's disease dyskinesia (on levodopa)Adults137 mg QHS274 mg QHS274 mg QHS
Parkinson's disease 'off' episodes (adjunct to levodopa/carbidopa)Adults137 mg QHS274 mg QHS274 mg QHS

Titration Increase after 1 week

Renal Moderate (CrCl 30-59): 68.5 mg QHS, max 137 mg QHS; Severe (15-29): 68.5 mg QHS; ESRD (<15): contraindicated

Hepatic Undefined

Contraindicated in end-stage renal disease

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Based on animal data, may cause fetal harm; no adequate human data

Lactation Amantadine excreted in human milk (amounts not quantified); may alter milk production

NO BOXED WARNINGS

Principal riskLivedo reticularis; confusion in renal impairment

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Amantadine ER ballicule

Amantadine ER ballicule: receptor binding, kinetics and half-life diagram

Open Amantadine ER in the interactive console ↗

Memory aids: mascots and interaction avatars

Amantadine ER SYMMETREL mascot mnemonic cartoon
“Symmetrical man to dine”
Amantadine ER weak base avatar
weak base

Open Amantadine ER in the interactive console ↗